PPARγ agonists (troglitazone and 15-deoxy-Δ12,14-prostaglandin J2) showed dose-dependent inhibitory effects on the proliferation of the gastric cancer cells, and their effect was augmented by the simultaneous addition of 9-cis retinoic acid, a ligand of RXRα. This evidence concerns the gene PPARG and gastric cancer.